Open AccessFrequency of T790M mutations after progression on epidermal growth factor receptor tyrosine kinase inhibitor in metastatic non-small cell lung cancer in Indian patients: real-time data from tertiary cancer hospital
Author(s) -
Venkata Pradeep Babu Koyyala,
Ullas Batra,
Parveen Jain,
Mukut Sharma,
Pankaj Goyal,
P. Medisetty,
Ankush Jajodia,
Udip Maheshwari
Publication year - 2018
Publication title -
lung india
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 25
eISSN - 0974-598X
pISSN - 0970-2113
DOI - 10.4103/lungindia.lungindia_451_17
Subject(s) - medicine , t790m , lung cancer , epidermal growth factor receptor , oncology , tyrosine kinase , tyrosine kinase inhibitor , cancer , cancer research , receptor , gefitinib
The aim of this study is to determine the incidence of T790M mutations after progression on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) and median duration on TKI before progression on TKI.